The FDA granted orphan-drug designation to ImmunoGen's lorvotuzumab mertasine as a treatment for small-cell lung cancer. The treatment previously obtained orphan-drug status for Merkel cell carcinoma in the U.S. and Europe.
Published in Brief:
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||